Home›Companies›Biotech & Pharma›MalarVx

MalarVx, Inc.

Develops vaccines to prevent malaria in people.

Updated Nov 9, 2026·Latest SEC filing Aug 25, 2026·Suggest an edit

About MalarVx

MalarVx is a private company based in Seattle, Washington. It has reported $1,175,000 raised in four offerings on Form D since October 2012. Its chief executive is James Davie.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 8, 2026Aug 25, 2026$125,000of $2.5M target2$62,500Promissory Note convertible into equity.Rule 506(b)Form D ↗
Not yetNov 23, 2015$0of $1.0M target0—EquityRule 506(b)Form D ↗
Jan 2, 2015Jan 20, 2015amended Jun 21, 2017$1,050,000of $1.5M target21$50,000EquityRule 506(b)Form D/A ↗2 earlier filings
Not yetOct 18, 2012$0of $250K target0—Equity04.1, 04.2Form D ↗
Total, four offerings$1,175,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on MalarVx's Form D filed Aug 25, 2026.

JH
Jodi Herczeg
Corporate Counsel
JD
James Davie
President & CEO, director

Sources

  1. SECMalarVx, Inc. Form D/A, filed Jan 30, 2015
  2. SECMalarVx, Inc. Form D, filed Jan 20, 2015
  3. SECMalarVx, Inc. filing history
  4. CompanyPrivacy policy
  5. CompanyContact
  6. CompanyAbout
  7. CompanyThe team
  8. PressMalarVx and HDT Bio license announcement